Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of romiplostim for injection in adlut
subjects with persistent or chronic primary immune thrombocytopenia (ITP).
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin China Pharmaceutical Co., LTD. Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.